Tag Archives: Steven Wardell

Chardan Capital Sticks to Its Buy Rating for Tivity Health Inc (TVTY)

Chardan Capital analyst Steven Wardell maintained a Buy rating on Tivity Health Inc (TVTY – Research Report) today and set a price target of $24. The company’s shares closed last Monday at $18.78, close to its 52-week low of $14.84.

Benefitfocus (BNFT) Receives a Hold from Chardan Capital

In a report released today, Steven Wardell from Chardan Capital maintained a Hold rating on Benefitfocus (BNFT – Research Report), with a price target of $27. The company’s shares closed last Monday at $26.48, close to its 52-week low of

Livongo Health Inc (LVGO) Has a New Rating from Chardan Capital

In a report released today, Steven Wardell from Chardan Capital initiated coverage with a Hold rating on Livongo Health Inc (LVGO – Research Report) and a price target of $40. The company’s shares closed last Monday at $34.03. Wardell wrote:

Invitae (NVTA) Gets a Buy Rating from Chardan Capital

In a report released yesterday, Steven Wardell from Chardan Capital reiterated a Buy rating on Invitae (NVTA – Research Report), with a price target of $30. The company’s shares closed yesterday at $19.91. Wardell wrote: “We liked the new strategic

Chardan Capital Sticks to Their Buy Rating for Model N (MODN)

In a report released today, Steven Wardell from Chardan Capital reiterated a Buy rating on Model N (MODN – Research Report), with a price target of $23. The company’s shares opened today at $18.33. Wardell said: “We liked the onboarding

Chardan Capital Thinks Tivity Health Inc’s Stock is Going to Recover

Chardan Capital analyst Steven Wardell maintained a Buy rating on Tivity Health Inc (TVTY – Research Report) today and set a price target of $31. The company’s shares opened today at $22.11, close to its 52-week low of $21.12. According